Can I Take St. John's Wort with BPC-157?

What Is BPC-157 and Why Does Its Metabolism Matter?

BPC-157 (body protection compound 157) is a 15-amino-acid synthetic peptide derived from a protein sequence found in human gastric juice. Preclinical data, largely from rodent models, show accelerated tendon healing, reduced gut inflammation, and central nervous system effects on dopamine and serotonin signaling. No Phase II or Phase III human trials have been published as of early 2025.

How the Body Processes BPC-157

Small peptides below roughly 1,500 daltons are generally cleaved by serum peptidases and intestinal brush-border enzymes rather than routed through hepatic CYP450 pathways. BPC-157's molecular weight is approximately 1,419 daltons. No published pharmacokinetic study in humans has identified it as a substrate of CYP3A4, CYP2D6, CYP2C9, or any other major cytochrome P450 isoform. This matters because the most feared herb-drug interactions with St. John's Wort are CYP-mediated, and BPC-157 does not appear to sit in that pathway.

Why This Does Not Mean "No Interaction"

Absence of CYP data is not the same as absence of risk. BPC-157 modulates nitric oxide (NO) synthesis and serotonin receptor sensitivity in animal studies [1]. St. John's Wort also acts on serotonin reuptake inhibition and NO pathways [2]. Two agents influencing the same signaling cascades can interact pharmacodynamically even when their absorption, distribution, metabolism, and excretion (ADME) profiles never overlap.

The Research Gap

A 2023 review in the journal Pharmaceuticals noted that BPC-157's precise receptor targets in humans remain unconfirmed and called for controlled pharmacokinetic trials before clinical protocols can be written with confidence [3]. Until those data exist, any interaction claim, in either direction, is speculative. Clinicians should document baseline symptom scores before any patient adds either compound.

How St. John's Wort Affects Drug Metabolism

St. John's Wort (Hypericum perforatum) is one of the most pharmacokinetically active botanicals in clinical use. The FDA issued a public health advisory in 2000 warning that St. John's Wort induces CYP3A4 and P-glycoprotein (P-gp), reducing plasma concentrations of co-administered drugs by 30-70% in documented cases [4].

CYP3A4 Induction: Mechanism and Timeline

Hyperforin, the constituent responsible for most of the CYP3A4 induction, activates the pregnane X receptor (PXR), which upregulates transcription of CYP3A4 and several membrane efflux transporters including P-gp and OATP1B1. The induction is dose-dependent: products standardized to 5% hyperforin show greater induction than low-hyperforin extracts [5]. Maximal induction occurs within 7-14 days of continuous use and reverses within 14 days of stopping.

Documented Clinical Examples

The magnitude of CYP3A4 induction by St. John's Wort is not trivial. In a controlled crossover study (N=12), co-administration with indinavir (an HIV protease inhibitor) reduced indinavir AUC by 57% [6]. Cyclosporine trough levels dropped by more than 50% in transplant recipients who started St. John's Wort, leading to acute rejection episodes. These are not edge cases. They represent the magnitude of interaction clinicians should keep in mind whenever St. John's Wort appears on a patient's supplement list.

P-Glycoprotein and Peptide Efflux

P-gp is an intestinal efflux pump that limits the oral bioavailability of many substrates. Whether BPC-157 taken orally (as opposed to subcutaneously or intramuscularly) is a P-gp substrate is unknown. If it were, St. John's Wort-driven P-gp upregulation could theoretically reduce oral BPC-157 absorption. Subcutaneous or intramuscular routes bypass this step entirely, which may explain why many clinical protocols favor injectable formulations for peptide delivery.

Pharmacodynamic Overlap: Where the Real Risk Lives

The more clinically plausible concern with combining BPC-157 and St. John's Wort is not CYP metabolism. It is the overlap in neurotransmitter systems.

Serotonin System Effects

St. John's Wort inhibits the reuptake of serotonin, dopamine, and norepinephrine, with serotonin reuptake inhibition being the best documented in vitro mechanism [7]. BPC-157, in rodent models, has been shown to modulate dopaminergic and serotonergic activity, partly through direct receptor interactions and partly through downstream effects on GABA and glutamate signaling [1]. Layering two serotonin-active compounds raises theoretical concern for serotonin syndrome, particularly at higher doses of either agent.

Serotonin syndrome, even in mild form, presents as tachycardia, diaphoresis, tremor, and agitation. It has been reported with combinations far less pharmacologically active than concurrent SSRI use. The Sternbach criteria and the Hunter Toxicity Decision Rules are the standard clinical tools for assessment [8].

Nitric Oxide Pathway

BPC-157 appears to upregulate endothelial nitric oxide synthase (eNOS) in animal models, contributing to angiogenesis and tissue repair [9]. St. John's Wort has been shown to modulate NO signaling in vascular endothelium as well, though the direction of effect varies by dose and tissue [2]. Whether these effects are additive, opposing, or neutral in humans is not established.

Mood and Anxiety Effects

St. John's Wort is most commonly self-prescribed for mild-to-moderate depression, with a 2008 Cochrane review (26 trials, N=3,320) finding it superior to placebo and similarly effective to standard antidepressants for mild depression with fewer side effects [10]. BPC-157 is anecdotally reported to reduce anxiety in some users, though no controlled human trial supports this. Combining two centrally active compounds without a clinician's supervision increases the difficulty of attributing any adverse effect to the correct agent.

Who Uses This Combination and Why

Most people asking about St. John's Wort and BPC-157 together are managing overlapping goals: tissue repair (BPC-157's primary research application) alongside mood support or mild depression (St. John's Wort's established use). They are typically not on prescription antidepressants, which explains why they have turned to a botanical and a research peptide rather than a pharmaceutical regimen.

The Self-Prescribing Pattern

Survey data from online peptide communities consistently show that BPC-157 users skew toward 35-55-year-old adults managing soft-tissue injuries, gut permeability concerns, or post-surgical recovery. St. John's Wort users in similar surveys cite cost and accessibility as primary motivations. When both are used simultaneously, the prescribing clinician is frequently unaware, because neither product requires a prescription in the United States in its usual form.

A Practical Risk-Stratification Framework

HealthRX's clinical team uses a three-tier approach when reviewing concurrent BPC-157 and St. John's Wort use in patients:

Tier 1 (Low Concern): Patient uses injectable BPC-157 subcutaneously at doses of 250-500 mcg per day and standard-dose St. John's Wort (300 mg TID, standardized to 0.3% hypericin). No other serotonergic medications present. Monitor for serotonin-related symptoms; no mandatory separation required, but document baseline mood and GI status.

Tier 2 (Moderate Concern): Patient uses oral BPC-157 alongside St. John's Wort and also takes any drug with a narrow therapeutic index (warfarin, cyclosporine, oral contraceptives, antiretrovirals). Require a 12-hour dose-separation minimum between agents and strongly recommend stopping St. John's Wort in favor of a clinician-supervised alternative.

Tier 3 (High Concern): Any concurrent serotonergic prescription drug (SSRI, SNRI, tramadol, triptans, linezolid) plus St. John's Wort plus BPC-157. Discontinue St. John's Wort immediately. Consult prescribing physician before resuming BPC-157.

Dose-Separation and Timing: What the Evidence Supports

Dose separation is frequently recommended for herb-drug combinations to reduce pharmacokinetic overlap at the intestinal absorption level. For CYP inducers like St. John's Wort, however, the interaction is enzymatic induction that takes days to weeks to establish and reverse. Spacing doses by 12 hours does not undo two weeks of CYP3A4 induction. The strategy has value mainly for P-gp-mediated absorption interference.

When Separation Helps

If BPC-157 is being taken orally and might share P-gp efflux with other oral substrates, taking it at least four hours before or after St. John's Wort may modestly reduce absorption competition. This is the same principle applied to separating St. John's Wort from levothyroxine, where a minimum two-hour separation is standard clinical advice.

When Separation Does Not Help

For CYP3A4-mediated interactions, the only meaningful intervention is stopping the inducer and waiting 14 days for enzyme activity to normalize. Since BPC-157 is not a confirmed CYP3A4 substrate, this concern does not apply directly. But any other CYP3A4-sensitive drug the patient is taking (oral contraceptives, statins, immunosuppressants) will continue to be affected throughout St. John's Wort use regardless of timing.

Washout Before Medical Procedures

Patients using St. John's Wort who are scheduled for surgery or any procedure involving anesthesia should discontinue it at least five half-lives before the procedure. Standard anesthesiology guidelines recommend stopping St. John's Wort at least 14 days before elective surgery due to interactions with anesthetic agents and prolonged sedation risk [11]. BPC-157 has no established pre-operative washout guideline, but disclosing its use to the anesthesiologist is still appropriate given its CNS activity in animal models.

Monitoring Parameters if Both Are Used

If a patient and their physician decide the benefit-risk balance supports concurrent use, specific monitoring checkpoints reduce the chance of a missed adverse event.

Baseline Assessment

Document resting heart rate, blood pressure, a brief mood screen (PHQ-9 is adequate), and any GI symptoms before starting either compound. BPC-157 is most studied in the context of gut mucosal repair, and St. John's Wort has mild GI side effects (nausea, dry mouth, dizziness in 2-5% of users) [10]. Separating a new GI complaint from a therapy-related one requires a baseline.

First 30 Days

Check in at two weeks for any serotonin-related symptoms: restlessness, increased sweating, fine tremor, or insomnia. These are early and reversible signs. Repeat the PHQ-9 at 30 days. If the patient is using oral BPC-157, ask whether GI tolerability has changed (bloating, altered motility).

Ongoing

If the patient is on any narrow-therapeutic-index drug alongside this combination, trough drug levels should be measured at four weeks, because St. John's Wort's induction peaks in that window. The FDA's drug interaction guidance for botanical products specifically lists this four-week window as the critical monitoring period [4].

Regulatory and Quality Considerations

Neither BPC-157 nor St. John's Wort is subject to pre-market safety review in the United States in the way prescription drugs are.

BPC-157 Legal Status

BPC-157 is not an FDA-approved drug. It is available through 503A compounding pharmacies when ordered by a licensed prescriber for individual patient use. In July 2023, the FDA sent warning letters to several compounders marketing BPC-157 as a drug product without an approved new drug application (NDA), citing adulteration and misbranding concerns. Patients should source BPC-157 only from pharmacies that can provide a certificate of analysis (COA) confirming identity, purity, and the absence of microbial contamination.

St. John's Wort Quality Variability

St. John's Wort is sold as a dietary supplement under DSHEA, meaning manufacturers are not required to prove efficacy or consistency before sale. Hyperforin content, the constituent driving CYP3A4 induction, varies widely across commercial products. A 2019 analysis of 27 commercially available St. John's Wort products found hyperforin concentrations ranging from nearly undetectable to 6.4% of extract weight, a 30-fold variance [12]. Products claiming standardization to 0.3% hypericin but with no statement about hyperforin content may have unpredictable CYP induction potential. Patients should select products that explicitly report hyperforin content per serving.

Special Populations

Patients on SSRIs or SNRIs

Adding St. John's Wort to an existing SSRI or SNRI is contraindicated by most clinical guidelines due to serotonin syndrome risk. Adding BPC-157 on top of that combination introduces an additional serotonergic variable in a system already under pharmacological load. This triple combination should not be used outside of direct physician supervision.

Post-Surgical Recovery

BPC-157 is sometimes used in post-surgical recovery for its putative tendon and muscle repair effects. Post-surgical patients are also among the most likely to be on immune-modulating or narrow-therapeutic-index drugs. St. John's Wort is explicitly contraindicated in transplant recipients on cyclosporine and in HIV patients on protease inhibitors because of CYP3A4-mediated drug level drops [4] [6]. Clinicians managing post-surgical BPC-157 use should obtain a complete supplement list, specifically asking about St. John's Wort.

Athletes and Performance Use

Some athletes combine BPC-157 for injury recovery with adaptogenic botanicals including St. John's Wort for mood and resilience support during rehabilitation. The World Anti-Doping Agency (WADA) does not currently list BPC-157 on its Prohibited List as of 2025, but detection methods are evolving. St. John's Wort is not prohibited. Athletes should nonetheless check current WADA lists at each competition cycle, as peptides face increasing scrutiny.

Clinical Bottom Line: Should You Combine Them?

The available evidence does not support an absolute contraindication between BPC-157 and St. John's Wort when both are used in isolation, at standard doses, without concurrent serotonergic prescription drugs. The pharmacokinetic interaction risk is low given BPC-157's peptide metabolism. The pharmacodynamic overlap in serotonin and nitric-oxide pathways is real but not quantified in human data.

The actionable questions for any patient considering this combination are specific:

1. Are you on any prescription drug that is a CYP3A4 substrate? If yes, St. John's Wort is likely already contraindicated regardless of BPC-157.
2. Are you on any serotonergic drug? If yes, adding St. John's Wort is contraindicated.
3. Is your BPC-157 sourced from a licensed 503A pharmacy with a current COA?
4. Has a licensed prescriber reviewed your complete medication and supplement list?

If all four answers are favorable, the combination falls into the "low concern, monitor closely" tier. A prescribing clinician should document the rationale for concurrent use and set explicit monitoring checkpoints at two and four weeks.

Patients who cannot confirm CYP3A4-free status for all their medications should discontinue St. John's Wort and discuss evidence-based depression or mood-support alternatives with their physician. The risks of unmonitored CYP3A4 induction in a polypharmacy context are among the best-documented herb-drug interaction risks in clinical medicine [4] [6].